|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,664.50 JPY | +2.26% |
|
-2.24% | -20.42% |
| 05-18 | US regulator greenlights AstraZeneca's blood pressure drug Baxfendy | AN |
| 05-17 | Daiichi Sankyo, AstraZeneca get US approvals for Enhertu | AN |
Business description: Daiichi Sankyo Company, Limited
Number of employees: 19,765
Sales by Activity: Daiichi Sankyo Company, Limited
| Fiscal Period: March | 2021 (JPY) | 2022 (JPY) | 2023 (JPY) | 2024 (JPY) | 2025 (JPY) |
|---|---|---|---|---|---|
Pharmaceutical Operation | 963B | 1,045B | 1,278B | 1,602B | 1,886B |
Geographical breakdown of sales: Daiichi Sankyo Company, Limited
| Fiscal Period: March | 2021 (JPY) | 2022 (JPY) | 2023 (JPY) | 2024 (JPY) | 2025 (JPY) |
|---|---|---|---|---|---|
United States of America | - | - | - | - | 642B |
Japan | 561B | 558B | 534B | 600B | 584B |
Europe | 114B | 139B | 205B | 311B | 418B |
Other Regions | 96.09B | 112B | 144B | 192B | 242B |
North America | 192B | 236B | 397B | 499B | - |
Executive Committee: Daiichi Sankyo Company, Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Hiroyuki Okuzawa
CEO | Chief Executive Officer | 62 | 31/03/2025 |
Tomohiro Kodama
DFI | Director of Finance/CFO | - | 31/03/2026 |
John Tsai
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/03/2026 |
Ueno Shizuko
CTO | Chief Tech/Sci/R&D Officer | 60 | 31/03/2020 |
Shangdai Cai
CMP | Compliance Officer | - | - |
Composition of the Board of Directors: Daiichi Sankyo Company, Limited
| Director | Title | Age | Since |
|---|---|---|---|
Hiroyuki Okuzawa
BRD | Director/Board Member | 62 | 20/06/2021 |
Yasuhiro Komatsu
BRD | Director/Board Member | 68 | 31/05/2022 |
| Director/Board Member | 62 | 16/06/2024 | |
Takaaki Nishii
BRD | Director/Board Member | 66 | 31/05/2023 |
Yo Honma
BRD | Director/Board Member | 70 | 16/06/2024 |
Ueno Shizuko
BRD | Director/Board Member | 60 | 22/06/2025 |
Kenneth Keller
BRD | Director/Board Member | 63 | 31/05/2025 |
Akihiro Watanabe
BRD | Director/Board Member | 67 | 22/06/2025 |
Reiko Kinoshita
BRD | Director/Board Member | 61 | 22/06/2025 |
Holdings: Daiichi Sankyo Company, Limited
| Name | Equities | % | Valuation |
|---|---|---|---|
| 60,523,331 | 3.19% | 1 000 M $ | |
| 6,129,000 | 1.06% | 108 M $ | |
CUORIPS INC. 12.09% | 1,000,000 | 12.09% | 43 M $ |
| 1,139,100 | 0.03% | 40 M $ | |
| 1,294,689 | 0.09% | 33 M $ | |
| 1,243,913 | 1.27% | 31 M $ | |
| 475,536 | 0.02% | 20 M $ | |
| 613,000 | 1.32% | 17 M $ | |
| 344,700 | 0.02% | 16 M $ | |
QOL HOLDINGS CO., LTD. 3.35% | 1,304,000 | 3.35% | 15 M $ |
Company details: Daiichi Sankyo Company, Limited
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Head Office Bldg, A&B
103-8426, Tokyo
+81 3 6225 1111
https://www.daiichisankyo.co.jp
Group companies: Daiichi Sankyo Company, Limited
| Name | Category and Sector |
|---|---|
Daiichi Sankyo Europe GmbH
 Daiichi Sankyo Europe GmbH Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Daiichi Sankyo Europe GmbH
Daiichi Sankyo Europe GmbH Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.26% | -2.24% | -27.46% | -46.40% | 29.85B | |
| +2.24% | +3.47% | +43.69% | +140.02% | 909B | |
| +1.05% | +0.40% | +51.28% | +47.72% | 552B | |
| +1.04% | +1.77% | +17.99% | +48.03% | 375B | |
| +0.59% | +2.53% | +24.56% | +13.82% | 332B | |
| +0.40% | +1.74% | +34.44% | +16.62% | 291B | |
| +0.59% | +2.09% | +27.82% | +31.74% | 287B | |
| +2.55% | +2.18% | +50.53% | +1.21% | 279B | |
| -1.47% | -5.03% | -37.71% | -50.58% | 199B | |
| +1.76% | +0.35% | +24.35% | +50.64% | 179B | |
| Average | +1.14% | +0.23% | +20.95% | +25.28% | 343.29B | |
| Weighted average by Cap. | +1.30% | +0.99% | +32.35% | +54.79% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4568 Stock
- Company Daiichi Sankyo Company, Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition